Product/Composition:- | Lenvatinib |
---|---|
Strength:- | 4 mg , 10 mg |
Form:- | Oral capsules |
Reference Brands:- | Lenvima® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Lenvatinib (brand name Lenvima®) is an oral tyrosine kinase inhibitor used to treat thyroid cancer, RCC, HCC, and endometrial cancer. Available in 4 mg and 10 mg capsules, it’s approved in the US and EU. Widely sourced by B2B pharma suppliers, Lenvatinib ensures GMP-compliant, reliable supply for oncology centers with competitive pricing.
Lenvatinib, marketed as Lenvima® by Eisai, is a potent oral tyrosine kinase inhibitor (TKI) used in oncology to treat thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma. Available in 4 mg and 10 mg capsules, Lenvatinib is approved in both the US and EU. It works by inhibiting tumor angiogenesis and cell proliferation. As a high-demand anticancer therapy, it is widely distributed by pharma B2B suppliers across the European and U.S. markets, ensuring GMP-compliant sourcing, consistent availability, and competitive pricing for hospitals, pharmacies, and oncology centers managing advanced cancers.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications